- Home
- ATAI
as 07-08-2024 4:00pm EST
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
| Founded: | 2018 | Country: | Germany |
| Employees: | N/A | City: | BERLIN |
| Market Cap: | 221.0M | IPO Year: | 2021 |
| Target Price: | $12.00 | AVG Volume (30 days): | 820.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.02 - $2.85 | Next Earning Date: | 08-08-2024 |
| Revenue: | $277,000 | Revenue Growth: | 2.97% |
| Revenue Growth (this year): | -2.55% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of ATAI Life Sciences N.V. (ATAI)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rao Srinivas | ATAI | See Remarks | Apr 2 '24 | Sell | $1.85 | 61,640 | $114,034.00 | 113,360 | SEC Form 4 |
| Johnson Anne Nagengast | ATAI | Chief Financial Officer | Apr 2 '24 | Sell | $1.85 | 27,410 | $50,708.50 | 73,590 | SEC Form 4 |
Latest ATAI Life Sciences N.V. News
ATAI Breaking Stock News: Dive into ATAI Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
GlobeNewswire
18 days ago
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
GOBankingRates
a month ago
5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
AFP
a month ago
Bumrah delivers as India beat Pakistan in low-scoring thriller
AFP
a month ago
Italy beat Bosnia in final Euros warm-up
AFP
a month ago
Trump loyalists proud to support 'felon' at Las Vegas rally
Business Insider
a month ago
US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia
Insider Monkey
a month ago
The Best Woody Perfume For Women
Share on Social Networks:
Disclaimer
The information presented on this page, "ATAI ATAI Life Sciences N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.